---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-021889"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:26:59.368435+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Oncocyte Q2 net loss $8.3M; plans RIF to cut $4.5M annual costs

## Summary
- Net loss $8.3M ($0.07 EPS) vs $10.5M ($0.12 EPS) YoY; revenue $2.1M, flat.
- Reduction in force to cut annual cash comp costs by >$4.5M; severance ~$2.0M in Q3 2022.
- Closed underwritten offering of $32.8M and preferred stock offering of $4.9M in net proceeds.
- Cash $47.1M as of June 30; annualized op expense reduction of ~$12M expected in 2023.
- Appointed Gisela Paulsen President & COO and Anish John CFO, effective Aug 8, 2022.

## SEC filing metadata
- accession: 0001493152-22-021889
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315222021889/0001493152-22-021889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315222021889/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-021889
- JSON: https://secwatch.observer/filing/0001493152-22-021889.json
- Plain text: https://secwatch.observer/filing/0001493152-22-021889.txt

## Key facts
- Executive change
  Anish John was appointed as Chief Financial Officer at Insight Molecular Diagnostics Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective August 8, 2022, the Board of Directors of the Company appointed Gisela Paulsen to the position of President and Chief Operating Officer and Anish John to the position of Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222021889/0001493152-22-021889-index.htm
- Executive change
  Gisela Paulsen was appointed as President and Chief Operating Officer at Insight Molecular Diagnostics Inc..
  - Action: appointed
  - Role: President and Chief Operating Officer
  source text: Effective August 8, 2022, the Board of Directors of the Company appointed Gisela Paulsen to the position of President and Chief Operating Officer and Anish John to the position of Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222021889/0001493152-22-021889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.